INVVY - Indivior PLC

Other OTC - Other OTC Delayed Price. Currency in USD
2.3000
-0.0200 (-0.86%)
At close: 1:36PM EST
Stock chart is not supported by your current browser
Previous Close2.3200
Open2.2900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.2900 - 2.3930
52 Week Range1.9750 - 7.9870
Volume2,022
Avg. Volume10,344
Market Cap330.659M
Beta (5Y Monthly)-0.58
PE Ratio (TTM)1.59
EPS (TTM)1.4500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 13, 2016
1y Target EstN/A
  • Moody's

    Indivior Finance S.ar.l. -- Moody's announces completion of a periodic review of ratings of RBP Global Holdings Ltd

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of RBP Global Holdings Ltd and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Did You Manage To Avoid Indivior's (LON:INDV) Devastating 87% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Indivior's (LON:INDV) Devastating 87% Share Price Drop?

    It's not possible to invest over long periods without making some bad investments. But you have a problem if you face...

  • Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder
    PR Newswire

    Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder

    Indivior PLC (LON: INDV) today announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) Study ™. RECOVER is a multisite, non-interventional cohort study examining long-term recovery in individuals with moderate to severe opioid use disorder who received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials (NCT02357901 and NCT02510014). ¹ The study design and participant characteristics of the RECOVER study can be found in Contemporary Clinical Trials.2 This study will be led by a team of researchers at the Fralin Biomedical Research Institute at Virginia Tech Carilion.

  • PR Newswire

    New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes

    Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed that study participants who were treated with SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII), demonstrated improved or maintained patient-centered outcomes across the following measures:

  • Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"
    PR Newswire

    Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"

    --Only 20% of people suffering from the disease receive any kind of treatment-- RICHMOND, Va. , Nov. 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the launch of a new direct-to-consumer (DTC) ...

  • PR Newswire

    Indivior 2019 Third Quarter and Nine Months Results Now Available; Conference Call With Leadership Today

    SLOUGH, England and RICHMOND, Va., Oct. 31, 2019 /PRNewswire/ -- Indivior PLC (INDV.L) today announced that its Q3/YTD 2019 results press release and investor supplement are now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. BST (8:00 a.m. EDT) on October 31, 2019.

  • Reuters

    UPDATE 2-New York, states reach $700 mln settlement with Reckitt over opioid probes

    New York and other states have reached a $700 million settlement deal with Reckitt Benckiser over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday. The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.

  • Is Indivior PLC (LON:INDV) Overpaying Its CEO?
    Simply Wall St.

    Is Indivior PLC (LON:INDV) Overpaying Its CEO?

    In 2014 Shaun Thaxter was appointed CEO of Indivior PLC (LON:INDV). This report will, first, examine the CEO...

  • PR Newswire

    Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative

    RICHMOND, Va., Sept. 26, 2019 /PRNewswire/ -- Indivior PLC (INDV.L) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled  "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose. Indivior's award is one of 375 grant awards across 41 states made by the NIH in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis.

  • These 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Safely
    Simply Wall St.

    These 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Safely

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Should Value Investors Consider Indivior (INVVY) Stock Now?
    Zacks

    Should Value Investors Consider Indivior (INVVY) Stock Now?

    Let's see if Indivior (INVVY) stock is a good choice for value-oriented investors right now from multiple angles.

  • Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Reuters

    UPDATE 1-Indivior profit rises on slower-than-expected Suboxone market share loss

    Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.

  • PR Newswire

    Indivior First Half 2019 Results Now Available; Conference Call With Leadership Today

    SLOUGH, England and RICHMOND, Va. , July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the ...

  • Reuters

    Indivior loses appeal to block generic Suboxone opioid treatments

    The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.

  • Reuters

    UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

    A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

  • PR Newswire

    Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m

    SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 ...

  • Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
    Reuters

    Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

    The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

  • Reuters

    UPDATE 2-Reckitt to pay $1.4 bln to end Indivior probe

    Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.